Concepedia

Enxiao Li

EL

Statistics

Publications

38

Citations

3K

H-Index

23

Active since

2013

Affiliations

First Affiliated Hospital of Xi'an Jiaotong University(Current)

Fudan University Shanghai Cancer Center

Harbin Medical University

Sichuan University

Chinese Academy of Medical Sciences & Peking Union Medical College

Enxiao Li is an author at First Affiliated Hospital of Xi'an Jiaotong University specializing in oncology, medicine, and molecular oncology.

Publications per year

2013–2024

38

Publications

38

Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial

Shukui Qin, Zhenggang Ren, Zhiqiang Meng et al. · The Lancet Oncology · 2020 · 638 citations

, , +9

Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial

Jianming Xu, Jie Shen, Shanzhi Gu et al. · Clinical Cancer Research · 2020 · 572 citations · Full text

, , +17

Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study

Zhi Peng, Tianshu Liu, Jia Wei et al. · Cancer Communications · 2021 · 202 citations · Full text

, , +16

Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study

Jianming Xu, Lin Shen, Zhiwei Zhou et al. · The Lancet Oncology · 2020 · 190 citations

, , +8

Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study

Jianming Xu, Lin Shen, Chunmei Bai et al. · The Lancet Oncology · 2020 · 189 citations

, , +11

1–5 of 38